Work

Abstract LB474: Impact of first-line (1L) amivantamab-lazertinib vs osimertinib on second-line (2L) progression-free survival (PFS)

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-lb474

Authors: David R. Spigel, Danny Nguyen, Hidetoshi Hayashi, Byoung Chul Cho, Sanjay Popat, James Chih-Hsin Yang, Scott Owen, Antonio Passaro, Clarissa Baldotto, Julian Kam, Seema Sethi, Sujay Shah, Jiarui Zhang, Joshua C. Curtin, Nicolas Girard, William N. William Jr

Institutions: Sarah Cannon, Tennessee Oncology, City Of Hope National Medical Center, Kindai University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, National Taiwan University Hospital, McGill University Health Centre, European Institute of Oncology, D’Or Institute for Research and Education, Johnson & Johnson (United States), Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154690076

Cites:

Cited by:

Related to: